Hoffmann-la Roche Inc.

Innov17 LLC

F. Hoffmann-la Roche Ag

Jefferson Wright Tilley

Richard W Kierstead

Robert W Guthrie

Achyutharao Sidduri

Nancy-Ellen Haynes

Waleed Danho

Nathan Robert Scott

Kenneth E Fahrenholtz

Kenneth Gregory Hull

Achytharao Sidduri

Yimin Qian

Paul Gillespie

Robert Alan Goodnow, Jr

Sung-Sau So

Nader Fotouhi

James Robert Blinn

Sherrie Lynn Pietranico-Cole

Kshitij Chhabilbhai Thakkar

Anderson Gaweco

Li Chen

Michael Robert Cohen

Robert Francis Kester

Kevin Richard Guertin

Steven Joseph Berthel

Agnieszka Kowalczyk

Joseph Swistok

John G Mullin

Wajiha Khan

Rolf Wagner

Shawn David Erickson

Fariborz Firooznia

Denis John Kertesz

Ramakanth Sarabu

Romyr Dominique

Kyungjin Kim

Tai-Nang Huang

Qi Qiao

Joseph Triscari

Lida Qi

George Kenneth Ehrlich

John Walker

David Charles Fry

Chang An Chu

Samantha Palmer

Gerald Lewis Kaplan

Hiroshi Watanabe

Ronald A LeMahieu

Eric Mertz

Tai-An Lin

Lee Apostle McDermott

Rebecca Taub

Warren William McComas

Qiang Zhang

John A Brinkman

Keiji Nakamura

Anish A Konkar

Michael Paul Myers

Karin Conde-Knape

Cristina Martha Rondinone

Patrizio Mattei

John W Clader

Matthew Michael Hamilton

Simona Maria Ceccarelli

Alexander Mayweg

Lichun Feng

Zhuming Zhang

Steven Gregory Mischke

Jin-Jun Liu

Allen John Lovey

Gary L Olson

Xin-Jie Chu

Qingjie Ding

Wendy Lea Corbett

Adrian Wai-Hing Cheung

Shian-Jan Shiuey

Odile Chomienne

Nan Jiang

Jenny Tan

Matthew Carson

Pamela Loreen Rossman

Mirjana Andjelkovic

Kevin W Anderson

William C Nason

Stuart Hayden

Prabha Saba Karnachi

Chun Ma

Michael J Kramer

Joseph Anthony Bilotta

Nicholas Marcopulos

Jagdish Kumar Racha

Hong Wang

Bruce Lester Banner

Ronald Andrew Le Mahieu

Jianping Lou

Nancy Ellen Haynes

John Guifoyle Mullin, Jr

David Young Jackson

David J Nelson

David F Kachensky

Guy P Heathers

Provided herein are compounds of the formulas (I) and (II): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.

Indazole retinoic acid receptor-related orphan receptor modulators and uses thereof

Provided herein are compounds of the formulas (I) and (II): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.  

Benzimidazole retinoic acid receptor-related orphan receptor modulators and uses thereof

The invention relates to ROR modulators; compositions comprising an effective amount of a ROR modulator; and methods for treating or preventing diseases associated with ROR.

ROR modulators and their uses

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.

Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.

Thyroid hormone analogs

The invention relates to ROR modulators; compositions comprising an effective amount of a ROR modulator; and methods for treating or preventing diseases associated with ROR. The invention is based in part on the discovery of ROR modulators which interact with RORa and/or RORy and thereby inhibit or induce RORa and/or RORy-activity, and RORa- and/or RORy-regulated target gene and protein expression.

The present invention provides compounds which are analogs of glucose-dependent insulinotropic polypeptide (GIP) and pharmaceutically acceptable salts of such compounds. These compounds have activity as agonists of GIP receptor.

Glucose-dependent insulinotropic peptide analogs

The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, Rand X are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Substituted naphthylacetic acids

Piperidinyl naphthylacetic acids

This invention relates to novel 4-dimethylaminobutyric acid derivatives of the formula wherein A, A, R, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments in methods for the treatment of diseases modulated by CPT2 inhibitors.

4-dimethylaminobutyric acid derivatives

Provided herein are neuropeptide-2 receptor agonists of the formula (I):Y&#x2014;R&#x2014;R&#x2014;X&#x2014;R&#x2014;R&#x2014;R&#x2014;R&#x2014;R&#x2014;R&#x2014;R&#x2014;R&#x2014;R&#x2014;R&#x2014;R&#x2014;R&#x2014;NH&#x2003;&#x2003;(I) (SEQ ID NO: 1),as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.

Neuropeptide-2 receptor (Y-2R) agonists

Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. X is 4-oxo-6-(1-piperazinyl)-3(4H)-quinazoline-acetic acid (Pqa). These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.

Neuropeptide-2 receptor (Y-2R) agonists and uses thereof

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Pyridazinone glucokinase activators

Azaindole glucokinase activators

Growing community of inventors

North Caldwell, NJ, United States of America

Jefferson Wright Tilley